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Abstract
Introduction:  The diagnosis and classification of fistulas based on anatomy, physiology and
etiological criteria is the first important stage, conservative treatment consists on patient's
stabilization. Finally, on complicated cases, when spontaneous closure fails, specific surgical
approach should be applied.
Case presentation: A 50 years-old women patient underwent four surgical interventions from
the bowel gangrene, caused from the superior mesenteric vein thrombosis consequences. After
fourth surgical intervention, at eighth post-operative day, the enterocutaneous fistula developed.
On 20-th day, after enterocutaneous fistula developed, together with TPN, we administered also
octreotide (100 micrograms/8 hours), for 48 hours. The reduction of fistula output, after treatment
of TPN in combination with octreotide, compare the treatment only with TPN, was not significant
(p < 0, 05). The enterocutaneous fistula, developed after fourth operation, has been spontaneously
closed after four months.
Conclusion: The fistula output, after treatment of TPN in combination with octreotide, compared
with the treatment only with TPN, wasn't significant, in our case, (p < 0,05). We think that the
optimum time for surgical treatment should not be based only on the period of time of conservative
treatment, but other factors should be taken on consideration like: the pathology that has indicated
the surgical treatment, the number of surgical interventions and period of time between these
interventions.
Introduction
In 75-85% of the cases the enterocutaneous fistulas
appear because of consequence of iatrogenic agents like
postoperative complications.
Approximately, in 15-25% of cases, gastrointestinal fistu-
las are spontaneous. Main causes are inflammatory bowel
diseases, ischemic bowel disease, radiotherapy, pancreas
malignancy etc. [1,2].
The diagnosing and classification of fistulas based on
anatomy, physiology and etiological criteria is the first
important stage. Conservative treatment consists on
patient's stability. Finally, in complicated cases, when
spontaneous closure fails, specific surgical treatment may
be implemented [3].
The most important physiologic and determinant factor
of fistulas is the daily output of intestinal fluid.
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Conservative treatment consists on the control of electro-
lytic disturbance, nutritional support with enteral nutri-
tion (EN), or parenteral and antibacterial therapy in the
cases with systemic sepsis signs, or local inflammation
accompanied with pain [4-7].
With the purpose to accelerate the spontaneous closure of
fistulas, now, together with TPN, the somatostatin-14 or
its synthetic analogue octreotide, can be given. In some
studies, it has been concluded that TPN together with
somatostatin-14, the closure time of fistulas can be
reduced [8,9].
The reason that we are doing this presentation is to
explain the effects of TPN, TPN in combination with
octreotide, in management of enterocutaneous fistula of
our case.
Case presentation
A 50 years old Kosovan Albanian woman underwent four
surgical interventions from the bowel gangrene, caused by
the superior mesenteric vein thrombosis.
First surgical intervention resulted with resection of 150
cm of small bowel with T-T primary anastomosis.
Three months later, she underwent second surgical treat-
ment. Intraoperationem, the small bowel (Ileum) gan-
grene has been ascertained about 35 cm, with free
perforation and presence of fibro-purulent liquid in abdo-
men. The resection of ileum (about 50 cm) was realized
and the ileostomy had been performed. The resection of
distal ileum has been made about 8 cm from the ileocoe-
cal valve and the remained part of ileum has been closed
blindly.
Upon the second operation, on the seventh post-operative
day, urgent surgical treatment was indicated. The patient
was in a very difficult healthy condition; cardiac, renal
and respiratory insufficiency with hypoalbuminemia
emerged (18 g/l). Intra-operation the jejunum gangrene
(5 cm), about 30 cm from Treitz ligament was ascertained.
The resection of jejunum (10 cm) was performed with T-
T primary anastomosis.
In ninth post-operative day, the enterocutaneous fistula
developed. The fistula output was high (800-1300 ml/24
hours). This amount gradually went decreasing, and the
fistula was closed spontaneously in thirteen days.
The patient was treated on Intensive Care Unit for 38 days.
After three months, the fourth surgical intervention was
realized which consisted on re-establishment bowel con-
tinuity. The proximal part of small bowel was primary
anastomosed with residual part of terminal ileum.
On the eighth post-operative day, the enterocutaneous fis-
tula developed. The treatment started with TPN.
During the first month, the fistula output behaves from
200-900 ml/24 hours. On 20-th day after enterocutane-
ous fistula developed, together with TPN, we adminis-
tered also octreotide (100 microgr./8 hours), for 48 hours.
The fistula output on 20-th day was 650 ml/24 hours, on
21-st day was 550 ml/24 hours, and on the 22-nd day, 520
ml/24 hours.
The reduction of fistula output, after treatment of TPN in
combination with octreotide, comparing the treatment
with TPN only, was not significant (p < 0.05).
Then, the octreotide administration stopped. The treat-
ment continued with TPN only.
At the second month, the fistula output was between 85 -
690 ml/24 hours.
At the third month, this amount reached up from 50-530
ml/24 hours, and at the fourth month this amount fluctu-
ated from 15-420 ml/24 hours. At the beginning of fifth
month, the fistula output was 2-15 ml/24 hours. The fis-
tula output after four days decreased in 2 ml/24 hours. For
two weeks this output remained constant (2 ml/24
hours), (see fig. 1)
After four months, the fistula has been closed spontane-
ously.
Now, two years have passed from the spontaneous fistula
closure. Although, there was less than 80 cm residual
small bowel, the patient has only 1-2 defecation/24
hours. She gained 14 kg.
The quality of her life is NORMAL.
Discussion
Once the enterocutaneous fistula is diagnosed, conserva-
tive treatment should start immediately [10].
Since 1970, the essence of treatment in enterocutaneous
fistula was an application of artificial nutrition in order to
stabilize the patient, to induct the interruption of gas-
trointestinal activity and antibiotic administration in
order to control the infection.
The application of TPN reduces the mortality rate and
increases the level of spontaneous closure up to 60% of
cases [5,11].
When the enterocutaneous fistula developed, TPN was
applied. With the purpose to decrease the time of sponta-Cases Journal 2009, 2:177 http://www.casesjournal.com/content/2/1/177
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neous closure of external gastrointestinal fistulas, lately,
pharmacological agent treatment has been investigated.
A study has ascertained that somatostatin-14, in combina-
tion with TPN, decreases the time of spontaneous closure
of fistula and significantly reduced the necessary time for
treatment with TPN (13.9 +/- 1.84 days somatostatine-14
+ TPN versus 20.4 +/- 2.98 days only with TPN, for (p <
0.05), and a consequent reduction in morbidity rate (35%
somatostatin-14 + TPN versus 68, 85% only with TPN, for
(p < 0.05), [8,9,12].
Two randomized studies, double blinded controlled and
one blinded study crossover, has investigated the role of
octreotide in gastrointestinal fistulas.
Only one of these studies ascertained the positive effect of
fistula output reduction after 24 hours of treatment (53%
reduction octreotide + TPN versus 9% TPN + placebo, n =
8 and n = 6, for p < 0.01).
Studies from Scott with C.A. and Sancho with C.A [13]
didn't prove any significant effect, after treatment with
octreotide in decreasing of fistula output.
The evidence suggests that if at the 1-st day, after somato-
statin-14 treatment + TPN, the fistula output decreases for
50%, this presents an prognostic indicator for spontane-
ous closure of fistula.
On 20-th day we have applied octreotide (100 microgr./8
hours) + TPN for 48 hours.
In the first day, the output reduction was 15.4%, mean-
time in second day this decrease was only 5.5%. This
reduction of the fistula output was not significant (p <
0,05). Then, we stopped treatment with octreotide. From
the other authors it has been recommended to stop treat-
ment with somatostatine-14 or octreotide, if, after 48
hours of treatment, there's no significant reduction of fis-
tula output [14].
Enterocutaneous fistula in our case, after third operation,
has been spontaneously closed after 13 days. The presence
of ileostomy only 50 cm from the fistula has given its con-
tribution. The enterocuteaneous fistula developed after
fourth operation, has been spontaneously closed after
four months.
In general, surgical treatment of enterocutaneous fistulas
is indicated if spontaneous closure fails after 30-60 days of
conservative treatment, although, in some cases, this treat-
ment can be delayed for three months. But so, the surgical
treatment is indicated if there is an obstruction distally of
fistula [15].
In our case, we didn't indicate surgical treatment, because
the patient had four surgical interventions. After these
interventions, only 80 cm of small bowel remained. Any
other intervention might cause a short bowel syndrome or
may complicate with the development of enterocutane-
ous fistula.
Conclusion
Although, in some investigations, it has been documented
the positive effects of somatostatine-14 or octreotide by
increasing of spontaneous fistula closure, in our case,
where we have administered octreotide, but there wasn't
significant decrease of fistula output after 48 hours of
administration.
We think that: the optimum time for surgical treatment
should not be based only on the long-time of conservative
treatment, but, other factors should be taken on consider-
ation, like:
1. The pathology that has indicated the surgical treatment,
2. The number of former surgical interventions and the
timeframe between these interventions
The conservative treatment, though prolonged, it may
lead to spontaneous closure of fistulas.
With all possible difficult complications in development,
even it is prolonged, in specific cases, the conservative
treatment should have higher advantages comparing with
the surgical treatment of enterocutaneous fistulas.
Comment
Changes on the study have been made in very careful
manner without changing its essence. Since there were no
Maximal fistula output throught months Figure 1
Maximal fistula output throught months.
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macroscopic changes on the bowel for the chronic inflam-
matory disease, the histopathology examination has not
been done. Thrombosis of vena mesenterica superior
made gangrenous changes with segmental character in the
small bowels (intestines). Enterocutaneous fistulae, after
the third operation, has evolved because the patient was
in severe condition with multi organ failure. While fistula
after the fourth operation evolved because anastomosis of
the small bowel was made 8 cm from ileocecal valve, a
high risk place for performing the anastomosis. The pur-
pose was to save the ileocecal valve and to save the impor-
tant physiological function of terminal ileum.
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